Jack Wallace
Stock Analyst at Guggenheim
(3.26)
# 915
Out of 4,667 analysts
22
Total ratings
59.09%
Success rate
0.46%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $210.63 | +18.22% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $0.95 | +531.58% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $21.79 | -21.98% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $7.36 | +90.22% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $194.38 | +13.18% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $18.52 | +115.98% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.84 | +1,175.51% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $22.23 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $210.63
Upside: +18.22%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $0.95
Upside: +531.58%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $21.79
Upside: -21.98%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $7.36
Upside: +90.22%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $194.38
Upside: +13.18%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $18.52
Upside: +115.98%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.84
Upside: +1,175.51%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $22.23
Upside: -